January 5, 2024 07:20 AM ESTUpdated 01:38 PM
People
R&D

AlloVir lays off 95% of staffers af­ter shut­ter­ing PhI­II an­tivi­ral cell ther­a­py tri­als 

Anna Brown

News Reporter

AlloVir is lay­ing off 95% of its work­ers to “re­duce costs and pre­serve cap­i­tal” af­ter dis­con­tin­u­ing three Phase III tri­als of its an­tivi­ral cell ther­a­py …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times